Stock BOT BOTANIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:53 2024-05-31 am EDT 		5-day change 1st Jan Change
0.29 AUD +3.57% Intraday chart for Botanix Pharmaceuticals Limited -3.33% +52.63%
May. 21 Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target MT
May. 13 Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy MT

Valuation

Fiscal Period: June 2019 2020 2024 2025 2026
Capitalization 1 139.3 37.94 456.8 - -
Enterprise Value (EV) 1 139.3 37.94 -9,143 -1,843 -27,743
P/E ratio -8.04 x -2.18 x -29 x 29 x 9.67 x
Yield - - - - -
Capitalization / Revenue 29 x 4.9 x 0.57 x 0.01 x 0.01 x
EV / Revenue 29 x 4.9 x -11.4 x -0.06 x -0.31 x
EV / EBITDA -8.18 x -2.31 x 0.78 x -0.17 x -0.43 x
EV / FCF -10.6 x -2.17 x 0.92 x 2.3 x -0.79 x
FCF Yield -9.44% -46% 108% 43.4% -127%
Price to Book 22.8 x 1.6 x - - -
Nbr of stocks (in thousands) 774,028 972,698 1,575,137 - -
Reference price 2 0.1800 0.0390 0.2900 0.2900 0.2900
Announcement Date 8/19/19 8/31/20 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2024 2025 2026
Net sales 1 4.811 7.744 800 30,500 89,200
EBITDA 1 -17.03 -16.41 -11,700 10,900 64,200
EBIT 1 -17.03 -16.51 -11,800 10,800 63,900
Operating Margin -354.04% -213.25% -1,475% 35.41% 71.64%
Earnings before Tax (EBT) 1 -17.04 -16.73 -11,700 10,900 64,000
Net income 1 -17.04 -16.73 -11,700 9,300 48,000
Net margin -354.15% -216.04% -1,462.5% 30.49% 53.81%
EPS 2 -0.0224 -0.0179 -0.0100 0.0100 0.0300
Free Cash Flow 1 -13.15 -17.45 -9,900 -800 35,300
FCF margin -273.4% -225.31% -1,237.5% -2.62% 39.57%
FCF Conversion (EBITDA) - - - - 54.98%
FCF Conversion (Net income) - - - - 73.54%
Dividend per Share - - - - -
Announcement Date 8/19/19 8/31/20 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - - 9,600 2,300 28,200
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 -13.2 -17.4 -9,900 -800 35,300
ROE (net income / shareholders' equity) -202% -138% -37.6% 21.2% 66.2%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 0.0100 0.0200 - - -
Cash Flow per Share - - - - -
Capex 1 - - - 800 2,200
Capex / Sales - - - 2.62% 2.47%
Announcement Date 8/19/19 8/31/20 - - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.29 AUD
Average target price
0.55 AUD
Spread / Average Target
+89.66%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BOTANIX PHARMACEUTICALS LIMITED Stock Botanix Pharmaceuticals Limited
+52.63% 303M
MERCK KGAA Stock Merck KGaA
+15.54% 78.51B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.05% 9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+58.17% 4.96B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-14.94% 4.84B
YUHAN CORPORATION Stock Yuhan Corporation
-.--% 3.72B
INDIVIOR PLC Stock Indivior PLC
+21.94% 2.48B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-26.63% 2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+16.75% 2.12B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-37.97% 1.94B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BOT Stock
  4. Financials Botanix Pharmaceuticals Limited